Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman
03:45pm, Monday, 23'rd Dec 2024
Evan Siegerman, BMO biotech analyst, joins 'Power Lunch' to discuss the big winners in the pharmaceutical space in 2025.
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
02:59pm, Monday, 23'rd Dec 2024
Shares of ResMed (RMD) and Inspire Medical Systems (INSP) fell Monday as the companies behind products to treat sleep apnea faced a new threat from weight-loss drugs.
Lilly Rises on FDA Approval of Weight-Loss Drug-Zepbound for Sleep Apnea
12:05pm, Monday, 23'rd Dec 2024
Eli Lilly's (LLY) Zepbound has received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea for adults with obesity, the drugmaker announced late Friday.
2 Sleep Apnea Stocks in Focus Today
10:51am, Monday, 23'rd Dec 2024
Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity -- the f
3 Big-Name Stocks Just Announced Big-Time Dividend Increases
10:47am, Monday, 23'rd Dec 2024
These three stocks, which are at or near the top of their respective industries, just increased dividends by double-digit percentages. Below, I'll reveal how much these companies are paying out to sha
Lilly obesity drug Mounjaro to be offered in Britain's NHS after watchdog nod
10:41am, Monday, 23'rd Dec 2024
Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after the drugs cost-effectiveness watchdog NICE on Monday gave its blessing.
LLY's Zepbound to Treat Sleep Apnea, QCOM Tops ARM in Court, Honda/Nissan Merger Talks
10:30am, Monday, 23'rd Dec 2024
Obesity drugmaker Eli Lilly (LLY) rises after Zepbound gets FDA approval for sleep apnea treatment. Meanwhile, Honda (HMC) and Nissan (NSANY) have begun merger discussions to potentially become the wo
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Monday, 23'rd Dec 2024
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Better Buy: Eli Lilly or Novo Nordisk?
09:30am, Monday, 23'rd Dec 2024
In this video, I will cover the recent updates regarding Novo Nordisk (NVO -17.83%) and whether or not the dip is worth buying over Eli Lilly (LLY 1.35%). Watch the short video to learn more, consider
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
09:21am, Monday, 23'rd Dec 2024
FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
Eli Lilly, Novo Nordisk Stocks Rise After One Just Hit a Landmark
07:32am, Monday, 23'rd Dec 2024
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.
Does This News From the FDA Make Eli Lilly a Buy for 2025?
04:15am, Monday, 23'rd Dec 2024
Eli Lilly (LLY 1.35%) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market.
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
02:51pm, Sunday, 22'nd Dec 2024
According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
3 Stocks That Could Join the Trillion-Dollar Market Cap Club Next Year
05:34am, Sunday, 22'nd Dec 2024
Believe it or not, there are now nine publicly traded U.S. companies worth $1 trillion or more.
2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves
08:43am, Saturday, 21'st Dec 2024
Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly boost your long-term returns by automatically reinvesting their payouts. Furt
